Successful treatment of systemic lupus erythematosus cerebritis with intravenous immunoglobulin

Clinical Rheumatology

Volumn 18, Issue 2, 1999, Pages 170-173

  Sherer, Y ^c   Levy, Y ^c   Langevitz, P ^c   Lorber, M ^a   Fabrizzi, F ^b   Shoenfeld, Y ^c  

^a RAMBAM MEDICAL CENTER   (Israel)

^b Clinical Trial Consultant   (Italy)

^c Department of Medicine 'B' ^*

Author keywords

Autoantibodies; Autoimmunity; Intravenous immunoglobulin; Neuropsychiatric lupus; Systemic lupus erythematosus

Indexed keywords

ACETAZOLAMIDE; ACETYLSALICYLIC ACID; COUMARIN; ENOXAPARIN; HYDROCORTISONE; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; PREDNISONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DIAGNOSTIC APPROACH ROUTE; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENCEPHALITIS; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NEUROPSYCHIATRY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME;

ADULT; AUTOANTIBODIES; COMPLEMENT C3; COMPLEMENT C4; ENCEPHALITIS; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOTHERAPY; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 0032903777     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s100670050079     Document Type: Article

References (23)

1. Schroeder JO, Zeuner RA, Euler HH, Loffler H. High dose intravenous immunoglobulins in systemic lupus erythematosus: clinical and serological results of a pilot study. J Rheumatol 1996;23:71-5.
2. Francioni C, Galeazzi M, Fioravanti A, Gelli R, Megale F, Marcolongo R. Long term I.V.Ig treatment in systemic lupus erythematosus. Clin Exp Rheum 1994;12:163-8.
3. Puddu P, De Pita O, Ruffelli M, Bellucci AM, Girardelli CR, Galeazzi M, et al. Intravenous immunoglobulin therapy: modification of the immunofluorescence pattern in the skin of six patients with systemic lupus erythematosus. Arthritis Rheum 1996;39:704-8.
4. Ruiz-Valverde MP, Segarra A, Tovar JL, Piera L. Treatment of systemic lupus erythematosus-associated thrombocytopenia with intravenous gamma globulin. Nephron 1994;67:500-1 [letter].
5. Aharon A, Levy Y, Bar-Dayan Y, Afek A, Zandman-Goddard G, Skurnik Y, et al. Successful treatment of early secondary myelofibrosis in SLE with IVIG. Lupus 1997;6:408-11.
6. Krause I, Blank M, Kopolovic J, Afek A, Golberg I, Tomer Y, et al. Abrogation of experimental systemic lupus erythematosus and primary antiphospholipid syndrome with intravenous gamma globulin. J Rheumatol 1995;22:1068-74.
7. West SG. Neuropsychiatrie lupus. Rheum Dis Clin North Am 1994;20:129-58.
8. Mitchell I, Webb M, Hughes R, Stewart J. Cerebral lupus. Lancet 1994;343:579-82.
9. Tomer Y, Shoenfeld Y. Successful treatment of psychosis secondary to SLE with high dose intravenous immunoglobulin. Clin Exp Rheumatol 1992;10:391-3.
10. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
11. Lockshin MD, Kagen LJ. Meningitis reactions after azathioprine. N Engl J Med 1972;286:1321-2.
12. Alosachie A, Terryberry JW, Mevorach D, Chapman Y, Lorber M, Torre D, et al. Central nervous system (CNS) involvement in SLE. Clin Rev Allergy lmmunol 1998;16:275-84.
13. Denburg JA, Denburg SD, Carbotte RM, Sakic B, Szechtman H. Nervous system lupus: pathogenesis and rationale for therapy. Scand J Rheumatol 1995;24:263-73.
14. Tincani A, Brey R, Balestrieri G, Vitali C, Doria A, Galeazzi M, et al. International survey on the management of patients with SLE. II. The results of a questionnaire regarding neuropsychiatrie manifestations. Clin Exp Rheumatol 1996;14(suppl):23-9.
15. Neuwelt CM, Lacks S, Kaye BR, Ellman JB, Borenstein DG. Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus. Am J Med 1995;98:32-41.
16. Pfausler B, Bosch S, Grubwieser G, Vollen H, Greil R, Hagn C, et al. Multimodal therapy in life-threatening cerebral lupus erythematosus: the benefit of cerebrospinal fluid pheresis. Int Arch Allergy Immunol 1995;107:592-4.
17. Corvetta A, Della Bitta R, Gabriella A, Spaeth PJ, Danieli G. Use of high-dose intravenous immunoglobulin in systemic lupus erythematosus: report of three cases. Clin Exp Rheumatol 1989;7:295-9.
18. Winder A, Molad Y, Ostfeld I, Kenet G, Pinkhas J, Sidi Y. Treatment of systemic lupus erythematosus by prolonged administration of high dose intravenous immunoglobulin: report of 2 cases. J Rheumatol 1993;20:495-8.
19. Ballow M. Mechanisms of action of intravenous immunoglobulin: clinical implications in autoimmune and inflammatory diseases. In: Kazatchkine MD, Morell A, editors. Intravenous immunoglobulin research and therapy. New York: Parthenon, 1996:123-8.
20. Brey RL, Amato AA, Kagan-Hallet K, Rhine CB, Stallworth CL. Anti-intercellular adhesion molecule-1 (ICAM-1) antibody treatment prevents central and peripheral nervous system disease in autoimmune-prone mice. Lupus 1997;6:645-51.
21. Bakimer R, Gilburd B, Zurgil N, Shoenfeld Y. The effect of intravenous-globulin on the induction of experimental anti-phospholipid sydnrome. Clin Immunol Immunopathol 1993;69:97-102.
22. Lafferty TE, DeHoratius RJ, Smith JB. Aseptic meningitis as a side effect of intravenous immune gammaglobulin. J Rheumatol 1997;24:2491-2.
23. Dalakas MC. Intravenous immune globulin therapy for neurologic diseases. Ann Intern Med 1997;126:721-30.